Breast Cancer Research and Treatment

, Volume 164, Issue 2, pp 429–436 | Cite as

Breast cancer treatment costs in younger, privately insured women

  • Benjamin T. Allaire
  • Donatus U. Ekwueme
  • Diana Poehler
  • Cheryll C. Thomas
  • Gery P. GuyJr.
  • Sujha Subramanian
  • Justin G. Trogdon



Younger women (under age 45 years) diagnosed with breast cancer often face more aggressive tumors, higher treatment intensity, lower survival rates, and greater financial hardship. The purpose of this study was to estimate breast cancer costs by stage at diagnosis during the first 18 months of treatment for privately insured younger women.


We analyzed North Carolina cancer registry data linked to claims data from private insurers from 2003 to 2010. Breast cancer patients were split into two cohorts: a younger and older group aged 21–44 and 45–64 years, respectively. We conducted a cohort study and matched women with and without breast cancer using age, ZIP, and Charlson Comorbidity Index. We calculated mean excess costs between breast cancer and non-breast cancer patients at 6, 12, and 18 months.


For younger women, AJCC 6th edition stage II cancer was the most common at diagnosis (40%), followed by stage I (34%). On the other hand, older women had more stage I (46%) cancer followed by stage II (34%). The excess costs for younger and older women at 12 months were $97,486 (95% confidence interval [CI] $93,631–101,341) and $75,737 (95% CI $73,962–77,512), respectively. Younger breast cancer patients had both a higher prevalence of later-stage disease and higher within-stage costs.


The study reports high costs of treatment for both younger and older women than a non-cancer comparison group; however, the estimated excess cost was significantly higher for younger women. The financial implications of breast cancer treatment costs for younger women need to be explored in future studies.


Breast cancer Medical care costs Private insurance Younger women Cancer stage 



Work on this study was supported by the Integrated Cancer Information and Surveillance System (ICISS), UNC Lineberger Comprehensive Cancer Center with funding provided by the University Cancer Research Fund (UCRF) via the State of North Carolina.

Funding support

This research was supported by contract number 200-2008-27958 Task Order 38 from the Centers for Disease Control and Prevention.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.


The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.


  1. 1.
    US Cancer Statistics Working Group (2015) United States cancer statistics: 1999–2013 Cancer incidence and mortality data.
  2. 2.
    Chollet-Hinton L, Anders CK, Tse C-K, Bell MB, Yang YC, Carey LA, Olshan AF, Troester MA (2016) Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. Breast Cancer Res 18(1):79CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36(3):237–249. doi: 10.1053/j.seminoncol.2009.03.001 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lee HB, Han W (2014) Unique features of young age breast cancer and its management. J Breast Cancer 17(4):301–307. doi: 10.4048/jbc.2014.17.4.301 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Breast Cancer Education And Awareness Requires Learning Young (EARLY) act of 2009 (HR 1740 111th).
  6. 6.
    Ekwueme DU, Trogdon JG (2016) The economics of breast cancer in younger women in the US. Am J Prev Med 50(2):249–254CrossRefPubMedGoogle Scholar
  7. 7.
    Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY (2003) Do young breast cancer patients have worse outcomes? J Surg Res 113(1):109–113CrossRefPubMedGoogle Scholar
  8. 8.
    Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4(11):e7695. doi: 10.1371/journal.pone.0007695 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405. doi: 10.1093/jnci/djr541 CrossRefPubMedGoogle Scholar
  10. 10.
    Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, Pollack LA (2014) Estimates of young breast cancer survivors at risk for infertility in the US. Oncologist 19(8):814–822. doi: 10.1634/theoncologist.2014-0016 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Allaire BT, Ekwueme DU, Guy GP, Li C, Tangka FK, Trivers KF, Sabatino SA, Rodriguez JL, Trogdon JG (2016) Medical care costs of breast cancer in privately insured women aged 18–44 years. Am J Prev Med 50(2):270–277CrossRefPubMedGoogle Scholar
  12. 12.
    Banegas MP, Guy GP Jr, de Moor JS, Ekwueme DU, Virgo KS, Kent EE, Nutt S, Zheng Z, Rechis R, Yabroff KR (2016) For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood) 35(1):54–61. doi: 10.1377/hlthaff.2015.0830 CrossRefGoogle Scholar
  13. 13.
    Wagner L, Lacey MD (2004) The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses. Clin J Oncol Nurs 8(3):279–287. doi: 10.1188/04.cjon.279-287 CrossRefPubMedGoogle Scholar
  14. 14.
    Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, Rowland JH (2013) Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119(20):3710–3717. doi: 10.1002/cncr.28262 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP (2016) Productivity costs associated with breast cancer among survivors aged 18–44 years. Am J Prev Med 50(2):286–294CrossRefPubMedGoogle Scholar
  16. 16.
    Fu AZ, Jhaveri M (2012) Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States. J Med Econ 15(4):688–694. doi: 10.3111/13696998.2012.673524 CrossRefPubMedGoogle Scholar
  17. 17.
    Barron JJ, Quimbo R, Nikam PT, Amonkar MM (2008) Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 109(2):367–377. doi: 10.1007/s10549-007-9650-4 CrossRefPubMedGoogle Scholar
  18. 18.
    Montero AJ, Eapen S, Gorin B, Adler P (2012) The economic burden of metastatic breast cancer: a US managed care perspective. Breast Cancer Res Treat 134(2):815–822. doi: 10.1007/s10549-012-2097-2 CrossRefPubMedGoogle Scholar
  19. 19.
    Blumen H, Fitch K, Polkus V (2016) Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits 9(1):23PubMedPubMedCentralGoogle Scholar
  20. 20.
    Segel JE (2006) Cost-of-illness studies—a primer. RTI-UNC Cent Excell Health Promot Econ.
  21. 21.
    Barlow WE (2009) Overview of methods to estimate the medical costs of cancer. Med Care 47(7 Suppl 1):S33CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    ICISS Data Resources. Integrated Cancer Information Center. Accessed 14 Oct 2015
  23. 23.
    Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMedGoogle Scholar
  24. 24.
    Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12):888–897CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Iacus SM, King G, Porro G (2009) CEM: software for coarsened exact matching. J Stat Softw 30:1–27CrossRefGoogle Scholar
  26. 26.
    American Joint Committee on Cancer (2009) Breast cancer staging, 7th ednGoogle Scholar
  27. 27.
    U.S. Bureau of Economic Data - National Data (2016) Table 1.1.9. Implicit price deflators for gross domestic products. Accessed 9 Mar 2015
  28. 28.
    Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 103:117–128CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Christinat A, Di Lascio S, Pagani O (2013) Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis 5(1):S36–S46PubMedPubMedCentralGoogle Scholar
  30. 30.
    Aebi S, Davidson T, Gruber G, Cardoso F, Group EGW (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Anna oncol 22(suppl 6):12–24Google Scholar
  31. 31.
    Rosenberg SM, Partridge AH (2015) Management of breast cancer in very young women. Breast (Edinburgh, Scotland) 24(Suppl 2):154–158. doi: 10.1016/j.breast.2015.07.036 CrossRefGoogle Scholar
  32. 32.
    Ribnikar D, Ribeiro J, Pinto D, Sousa B, Pinto A, Gomes E, Moser E, Cardoso M, Cardoso F (2015) Breast cancer under age 40: a different approach. Curr Treat Options Oncol 16(4):1–24CrossRefGoogle Scholar
  33. 33.
    Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100(9):630–641. doi: 10.1093/jnci/djn103 CrossRefPubMedGoogle Scholar
  34. 34.
    Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C (2011) Cost of breast cancer treatment in medicaid: implications for state programs providing coverage for low-income women. Med Care 49(1):89–95. doi: 10.1097/MLR.0b013e3181f81c32 CrossRefPubMedGoogle Scholar
  35. 35.
    US Preventative Services Task Force (2016). Final Recommendation Statement -  Breast Cancer Screening Recommendations. Accessed 15 Mar 2016
  36. 36.
    Centers for Disease Control and Prevention (2016) Bring Your Brave campaign.
  37. 37.
    Korde LA, Partridge AH, Esser M, Lewis S, Simha J, Johnson RH (2015) Breast Cancer in Young Women: Research Priorities. A report of the young survival coalition research think tank meeting. J Adolesc Young Adult Oncol 4(1):34–43CrossRefPubMedGoogle Scholar
  38. 38.
    Yabroff KR, Dowling EC, Guy GP Jr, Banegas MP, Davidoff A, Han X, Virgo KS, McNeel TS, Chawla N, Blanch-Hartigan D, Kent EE, Li C, Rodriguez JL, de Moor JS, Zheng Z, Jemal A, Ekwueme DU (2016) Financial hardship associated with cancer in the United States: findings From a population-based sample of adult cancer survivors. J Clin Oncol 34(3):259–267. doi: 10.1200/jco.2015.62.0468 CrossRefPubMedGoogle Scholar
  39. 39.
    Farooqi B, Smith B, Chowdhary M, Pavoni S, Modi A, Schnell F (2015) Racial disparities in breast cancer diagnosis in Central Georgia in the United States. J Commun Support Oncol 13(12):436–441. doi: 10.12788/jcso.0179 CrossRefGoogle Scholar
  40. 40.
    Short PF, Moran JR, Punekar R (2011) Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 117(12):2791–2800. doi: 10.1002/cncr.25835 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.RTI International, Research Triangle ParkDurhamUSA
  2. 2.Centers for Disease Control and PreventionAtlantaGeorgia
  3. 3.University of North CarolinaChapel HillUSA

Personalised recommendations